Newsoara HYK Biopharmaceuticals Co., Ltd.

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
No discrete molecular targetOncolytic virus
Non-Small Cell Lung CancerOvarian Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Olvimulogene nanivacirepvecPhase 3Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
Est. primary completion 2026-12 · NCT05281471 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Olvimulogene nanivacirepvecPhase 2Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma …
Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.